Japan and Singapore in regulatory information exchange agreement
This article was originally published in Clinica
Japan and Singapore have agreed to exchange confidential information on the regulation of drugs, medical devices and cosmetics.
You may also be interested in...
Now that the UK has left the EU, the UK’s medicines regulator says it will use the rest of this year to work out how best to ensure continuity of drug regulation after the Brexit transition period ends on 31 December.
Securing accelerated assessment for a drug in any regulatory jurisdiction is a major boost for drug companies, but it does not necessarily translate into an earlier reimbursement decision.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.